Haematological malignancies in sibling and unrelated donors of allogeneic peripheral stem cells mobilised with G-CSF filgrastim: a transplant centre and Czech National Marrow Donors Registry experience

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F12%3A10135328" target="_blank" >RIV/00669806:_____/12:10135328 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.nature.com/bmt/journal/v47/n6/pdf/bmt2011173a.pdf" target="_blank" >http://www.nature.com/bmt/journal/v47/n6/pdf/bmt2011173a.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/bmt.2011.173" target="_blank" >10.1038/bmt.2011.173</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Haematological malignancies in sibling and unrelated donors of allogeneic peripheral stem cells mobilised with G-CSF filgrastim: a transplant centre and Czech National Marrow Donors Registry experience

Popis výsledku v původním jazyce

G-CSF filgrastim is frequently used to mobilise CD34? cells in donors before PBSC collection. Several observational reports raised concerns regarding an elevated risk of haematological malignancies after G-CSF administration. It was found that treatmentwith G-CSF of PBSC donors induced chromosomal tetraploidy in a small subset of mature myeloid cells in the blood,1 epigenetic and genetic alterations in lymphocytes2 and aneuploidy.3 In 2006, Bennett et al.4 reported two cases of AML identified in the sibling donors, whose recipients also suffered with AML, among 200 individuals who had received filgrastim before collection of PBSC for allogeneic transplantation. In a large retrospective EBMT analysis, Halter et al.5 observed 20 haematological malignancies (3.92/10 000), of which 12 were after donating PBSC; however, the observed incidence rate did not exceed the expected incidence in an age- and sex-adjusted general population, and there was no relationship with the type of haematologi

Název v anglickém jazyce

Haematological malignancies in sibling and unrelated donors of allogeneic peripheral stem cells mobilised with G-CSF filgrastim: a transplant centre and Czech National Marrow Donors Registry experience

Popis výsledku anglicky

G-CSF filgrastim is frequently used to mobilise CD34? cells in donors before PBSC collection. Several observational reports raised concerns regarding an elevated risk of haematological malignancies after G-CSF administration. It was found that treatmentwith G-CSF of PBSC donors induced chromosomal tetraploidy in a small subset of mature myeloid cells in the blood,1 epigenetic and genetic alterations in lymphocytes2 and aneuploidy.3 In 2006, Bennett et al.4 reported two cases of AML identified in the sibling donors, whose recipients also suffered with AML, among 200 individuals who had received filgrastim before collection of PBSC for allogeneic transplantation. In a large retrospective EBMT analysis, Halter et al.5 observed 20 haematological malignancies (3.92/10 000), of which 12 were after donating PBSC; however, the observed incidence rate did not exceed the expected incidence in an age- and sex-adjusted general population, and there was no relationship with the type of haematologi

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bone Marrow Transplantation

ISSN

0268-3369

e-ISSN

—

Svazek periodika

47

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

2

Strana od-do

867-868

Kód UT WoS článku

000305276200016

EID výsledku v databázi Scopus

—